ARWR (Arrowhead Pharmaceuticals) Tariff Resilience Score: 8/10 (As of Jul. 01, 2026)


ARWR Arrowhead Pharmaceuticals Inc ARWR
49 GF Score
Price $80.59
GF Value $51.68
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Arrowhead Pharmaceuticals Tariff Resilience Score?

Arrowhead Pharmaceuticals ARWR -1.20% 49 Tariff Resilience Score is 8 as of Jul. 01, 2026. GuruFocus rates ARWR with a GF Score™ of 49/100 and a GF Value™ of $51.68 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,374 Biotechnology companies, Arrowhead Pharmaceuticals ranks better than 98.69% on this metric.

Arrowhead Pharmaceuticals has the Tariff Resilience Score of 8, which implies that the company might have Highly Resilient.

Arrowhead Pharmaceuticals has Arrowhead Pharmaceuticals Inc has high resilience to tariffs due to its focus on R&D and limited manufacturing exposure. The pharmaceutical industry often enjoys tariff exemptions, and the company has not faced significant historical impacts.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Arrowhead Pharmaceuticals might have Highly Resilient.

Arrowhead Pharmaceuticals  (NAS:ARWR) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Arrowhead Pharmaceuticals Tariff Resilience Score Related Terms

ARWR vs CYTK, TECH, KRYS: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Arrowhead Pharmaceuticals's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arrowhead Pharmaceuticals Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arrowhead Pharmaceuticals's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Arrowhead Pharmaceuticals's Tariff Resilience Score falls into.


ARWR
49GF Score
Arrowhead Pharmaceuticals Inc ARWR
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 8 mean?
Arrowhead Pharmaceuticals (ARWR) has a Tariff Resilience Score of 8 as of Jul. 01, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Arrowhead Pharmaceuticals ranks #18 out of 1374 companies in the Biotechnology industry, placing it in the top 1.3%.
Is Arrowhead Pharmaceuticals' Tariff Resilience Score too high?
Arrowhead Pharmaceuticals' current Tariff Resilience Score is 8. The Biotechnology industry median Tariff Resilience Score is 4.00. Arrowhead Pharmaceuticals' value of 8 is 100% above this industry median. Based on the distribution chart, Arrowhead Pharmaceuticals ranks #18 out of 1374 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Arrowhead Pharmaceuticals has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Arrowhead Pharmaceuticals' Tariff Resilience Score compare to CYTK and TECH?
According to the Biotechnology industry distribution chart, Arrowhead Pharmaceuticals ranks #18 out of 1374 companies for Tariff Resilience Score. This places Arrowhead Pharmaceuticals in the top 1% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Arrowhead Pharmaceuticals' value of 8 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,374 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arrowhead Pharmaceuticals's current Tariff Resilience Score of 8 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arrowhead Pharmaceuticals's current Tariff Resilience Score is 8. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arrowhead Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Arrowhead Pharmaceuticals (ARWR) is currently considered Significantly Overvalued. The stock's GF Value™ is $51.68, compared to a current price of $80.59 — trading 55.9% above its estimated fair value. The current Tariff Resilience Score is 8 and 100% above the Biotechnology industry median of 4.00. Arrowhead Pharmaceuticals' overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Arrowhead Pharmaceuticals (ARWR), the current Tariff Resilience Score is 8 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arrowhead Pharmaceuticals (ARWR) Overvalued in 2026?

Based on GuruFocus' analysis, Arrowhead Pharmaceuticals stock appears to be overvalued. The current stock price of $80.59 is trading 55.9% above its estimated GF Value™ of $51.68. GuruFocus considers Arrowhead Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for ARWR:

  • Tariff Resilience Score: 8
  • GF Value™: $51.68 vs. price of $80.59 (55.9% above fair value)
  • GF Score™: 49/100 with 7 warning signs
  • Industry Position: 100% above the Biotechnology median (#18 of 1374)

No single metric tells the full story. See the ARWR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arrowhead Pharmaceuticals Business Description

Address 177 E Colorado Boulevard, Suite 700, Pasadena, CA, USA, 91105
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
49GF Score

Get the complete analysis for ARWR

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$80.59
Price
$51.68
GF Value